The impact of initial tumor response on survival outcomes of patients with HER2-positive advanced breast cancer treated with docetaxel, trastuzumab, and pertuzumab: an exploratory analysis of the…

Overview of attention for article published in Clinical Breast Cancer, February 2024

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#42 of 1,072)
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

So far, Altmetric has seen 27 X posts from 27 X users, with an upper bound of 105,273 followers.

RT @Martha__Carlson: Analysis about the outcome differences in HER2+advanced breast cancer for complete response (NED for us pts) vs partia…

RT @Martha__Carlson: Analysis about the outcome differences in HER2+advanced breast cancer for complete response (NED for us pts) vs partia…

RT @Martha__Carlson: Analysis about the outcome differences in HER2+advanced breast cancer for complete response (NED for us pts) vs partia…

RT @Martha__Carlson: Analysis about the outcome differences in HER2+advanced breast cancer for complete response (NED for us pts) vs partia…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 23 additional X posts.